开云app官网登录入口网页版-官方正版

[GetPortalCommentsPageByObjectIdResponse(id=2221084, encodeId=a57722210849a, content=投过3篇GC第一次让大修，各位大佬GC给机会修稿中的概率怎么样。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231102/0c9e5413f4ba4bbdb156bc2a2418ce2e/0236291df9e84588a5c221c5f3033605.jpeg, createdBy=079f1702729, createdName=记录投稿经历, createdTime=Sun Aug 18 13:44:28 CST 2024, time=2024-08-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2124654, encodeId=c2562124654db, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：分子;肿瘤;基础 经验分享：一审一个多月，两个审稿人很专业，给了两个月时间 major revision。二审十天，minor revision 当天修回后三天accept。 编辑的效率非常高，submit后第二天就with editor，隔天就under review。非常不错的杂志，影响因子和声誉都在稳步上升。 目前发文量减少，还是以临床文章为主，缺乏优质的基础研究，希望越办越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=241, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5015158554, createdName=146afc57m84暂无昵称, createdTime=Sun Apr 09 22:11:45 CST 2023, time=2023-04-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=582852, encodeId=6ac958285252, content=我想问一下，送审的话，状态还是under review吗？还是说会改变？asp 2019-02-21 18:52:00 发表: 投了一篇，大修后接受，编辑审稿人效率高。, beContent=asp 2019-02-21 18:52:00 发表: 投了一篇，大修后接受，编辑审稿人效率高。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6715139146, createdName=146715bem82(暂无昵称), createdTime=Tue Jan 07 00:00:00 CST 2020, time=2020-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583965, encodeId=9b6758396532, content=老师，您好，请问这个杂志的版面费贵么nelsontsai 2018-04-27 00:00:00 发表: 投了两篇.一篇审稿约1月拒稿.另一篇一审20天.大修.一个月厚修回.两周接收.编辑和审稿人都很nice.很快., beContent=nelsontsai 2018-04-27 00:00:00 发表: 投了两篇.一篇审稿约1月拒稿.另一篇一审20天.大修.一个月厚修回.两周接收.编辑和审稿人都很nice.很快., objectType=tool_impact_factor, channel=null, level=null, likeNumber=234, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0c002335043, createdName=1227ad64m36暂无昵称, createdTime=Wed Jan 29 00:00:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201934, encodeId=6fb1220193441, content=二审有under review吗？with editor多久能under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6fe5386329, createdName=Jojo, createdTime=Mon May 06 08:53:30 CST 2024, time=2024-05-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=849606, encodeId=99ad84960665, content=审稿速度较快，但是对临床的部分要求严格。给了大修意见，二审四天接收。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=236, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e0b5414039, createdName=ms9688259418763462, createdTime=Sun Feb 03 07:34:23 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567070, encodeId=640556e07089, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：投了一篇，大修后接受，编辑审稿人效率高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=248, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJMC3tF03dm1t2TEOSN9Hiba2iagxaIW7O4RMcQJEESwLxBY5sgv2v1eyXOZd0e7xng6eLxqp7PoSAw/132, createdBy=c2d31631094, createdName=asp, createdTime=Thu Feb 21 18:52:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570704, encodeId=7c095e07046f, content=它收纳肝癌相关的文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/22/0ddfb5f93bf4092dfab0f122ddd93d58.jpg, createdBy=e5902208056, createdName=120cc505m10(暂无昵称), createdTime=Thu May 09 23:30:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183259, encodeId=5d9e218325951, content=偏重的研究方向：肿瘤 经验分享：请问一下这个期刊可以投稿综述吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bef79115167, createdName=ms5000001363351337, createdTime=Mon Jan 22 19:39:14 CST 2024, time=2024-01-22, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2153588, encodeId=9d152153588ef, content=大家几天才变成with editor呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df182456760, createdName=1240adaem89暂无昵称, createdTime=Sat Aug 19 13:53:23 CST 2023, time=2023-08-19, status=1, ipAttribution=四川省)]

2024-08-18 记录投稿经历来自广东省

投过3篇GC第一次让大修，各位大佬GC给机会修稿中的概率怎么样。

56 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2221084, encodeId=a57722210849a, content=投过3篇GC第一次让大修，各位大佬GC给机会修稿中的概率怎么样。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231102/0c9e5413f4ba4bbdb156bc2a2418ce2e/0236291df9e84588a5c221c5f3033605.jpeg, createdBy=079f1702729, createdName=记录投稿经历, createdTime=Sun Aug 18 13:44:28 CST 2024, time=2024-08-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2124654, encodeId=c2562124654db, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：分子;肿瘤;基础 经验分享：一审一个多月，两个审稿人很专业，给了两个月时间 major revision。二审十天，minor revision 当天修回后三天accept。 编辑的效率非常高，submit后第二天就with editor，隔天就under review。非常不错的杂志，影响因子和声誉都在稳步上升。 目前发文量减少，还是以临床文章为主，缺乏优质的基础研究，希望越办越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=241, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5015158554, createdName=146afc57m84暂无昵称, createdTime=Sun Apr 09 22:11:45 CST 2023, time=2023-04-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=582852, encodeId=6ac958285252, content=我想问一下，送审的话，状态还是under review吗？还是说会改变？asp 2019-02-21 18:52:00 发表: 投了一篇，大修后接受，编辑审稿人效率高。, beContent=asp 2019-02-21 18:52:00 发表: 投了一篇，大修后接受，编辑审稿人效率高。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6715139146, createdName=146715bem82(暂无昵称), createdTime=Tue Jan 07 00:00:00 CST 2020, time=2020-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583965, encodeId=9b6758396532, content=老师，您好，请问这个杂志的版面费贵么nelsontsai 2018-04-27 00:00:00 发表: 投了两篇.一篇审稿约1月拒稿.另一篇一审20天.大修.一个月厚修回.两周接收.编辑和审稿人都很nice.很快., beContent=nelsontsai 2018-04-27 00:00:00 发表: 投了两篇.一篇审稿约1月拒稿.另一篇一审20天.大修.一个月厚修回.两周接收.编辑和审稿人都很nice.很快., objectType=tool_impact_factor, channel=null, level=null, likeNumber=234, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0c002335043, createdName=1227ad64m36暂无昵称, createdTime=Wed Jan 29 00:00:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201934, encodeId=6fb1220193441, content=二审有under review吗？with editor多久能under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6fe5386329, createdName=Jojo, createdTime=Mon May 06 08:53:30 CST 2024, time=2024-05-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=849606, encodeId=99ad84960665, content=审稿速度较快，但是对临床的部分要求严格。给了大修意见，二审四天接收。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=236, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e0b5414039, createdName=ms9688259418763462, createdTime=Sun Feb 03 07:34:23 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567070, encodeId=640556e07089, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：投了一篇，大修后接受，编辑审稿人效率高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=248, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJMC3tF03dm1t2TEOSN9Hiba2iagxaIW7O4RMcQJEESwLxBY5sgv2v1eyXOZd0e7xng6eLxqp7PoSAw/132, createdBy=c2d31631094, createdName=asp, createdTime=Thu Feb 21 18:52:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570704, encodeId=7c095e07046f, content=它收纳肝癌相关的文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/22/0ddfb5f93bf4092dfab0f122ddd93d58.jpg, createdBy=e5902208056, createdName=120cc505m10(暂无昵称), createdTime=Thu May 09 23:30:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183259, encodeId=5d9e218325951, content=偏重的研究方向：肿瘤 经验分享：请问一下这个期刊可以投稿综述吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bef79115167, createdName=ms5000001363351337, createdTime=Mon Jan 22 19:39:14 CST 2024, time=2024-01-22, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2153588, encodeId=9d152153588ef, content=大家几天才变成with editor呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df182456760, createdName=1240adaem89暂无昵称, createdTime=Sat Aug 19 13:53:23 CST 2023, time=2023-08-19, status=1, ipAttribution=四川省)]

2023-04-09 146afc57m84暂无昵称来自江苏省

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：分子;肿瘤;基础
经验分享：一审一个多月，两个审稿人很专业，给了两个月时间 major revision。二审十天，minor revision 当天修回后三天accept。
编辑的效率非常高，submit后第二天就with editor，隔天就under review。非常不错的杂志，影响因子和声誉都在稳步上升。
目前发文量减少，还是以临床文章为主，缺乏优质的基础研究，希望越办越好。

241 9

展开9条回复

[GetPortalCommentsPageByObjectIdResponse(id=2221084, encodeId=a57722210849a, content=投过3篇GC第一次让大修，各位大佬GC给机会修稿中的概率怎么样。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231102/0c9e5413f4ba4bbdb156bc2a2418ce2e/0236291df9e84588a5c221c5f3033605.jpeg, createdBy=079f1702729, createdName=记录投稿经历, createdTime=Sun Aug 18 13:44:28 CST 2024, time=2024-08-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2124654, encodeId=c2562124654db, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：分子;肿瘤;基础 经验分享：一审一个多月，两个审稿人很专业，给了两个月时间 major revision。二审十天，minor revision 当天修回后三天accept。 编辑的效率非常高，submit后第二天就with editor，隔天就under review。非常不错的杂志，影响因子和声誉都在稳步上升。 目前发文量减少，还是以临床文章为主，缺乏优质的基础研究，希望越办越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=241, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5015158554, createdName=146afc57m84暂无昵称, createdTime=Sun Apr 09 22:11:45 CST 2023, time=2023-04-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=582852, encodeId=6ac958285252, content=我想问一下，送审的话，状态还是under review吗？还是说会改变？asp 2019-02-21 18:52:00 发表: 投了一篇，大修后接受，编辑审稿人效率高。, beContent=asp 2019-02-21 18:52:00 发表: 投了一篇，大修后接受，编辑审稿人效率高。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6715139146, createdName=146715bem82(暂无昵称), createdTime=Tue Jan 07 00:00:00 CST 2020, time=2020-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583965, encodeId=9b6758396532, content=老师，您好，请问这个杂志的版面费贵么nelsontsai 2018-04-27 00:00:00 发表: 投了两篇.一篇审稿约1月拒稿.另一篇一审20天.大修.一个月厚修回.两周接收.编辑和审稿人都很nice.很快., beContent=nelsontsai 2018-04-27 00:00:00 发表: 投了两篇.一篇审稿约1月拒稿.另一篇一审20天.大修.一个月厚修回.两周接收.编辑和审稿人都很nice.很快., objectType=tool_impact_factor, channel=null, level=null, likeNumber=234, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0c002335043, createdName=1227ad64m36暂无昵称, createdTime=Wed Jan 29 00:00:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201934, encodeId=6fb1220193441, content=二审有under review吗？with editor多久能under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6fe5386329, createdName=Jojo, createdTime=Mon May 06 08:53:30 CST 2024, time=2024-05-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=849606, encodeId=99ad84960665, content=审稿速度较快，但是对临床的部分要求严格。给了大修意见，二审四天接收。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=236, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e0b5414039, createdName=ms9688259418763462, createdTime=Sun Feb 03 07:34:23 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567070, encodeId=640556e07089, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：投了一篇，大修后接受，编辑审稿人效率高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=248, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJMC3tF03dm1t2TEOSN9Hiba2iagxaIW7O4RMcQJEESwLxBY5sgv2v1eyXOZd0e7xng6eLxqp7PoSAw/132, createdBy=c2d31631094, createdName=asp, createdTime=Thu Feb 21 18:52:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570704, encodeId=7c095e07046f, content=它收纳肝癌相关的文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/22/0ddfb5f93bf4092dfab0f122ddd93d58.jpg, createdBy=e5902208056, createdName=120cc505m10(暂无昵称), createdTime=Thu May 09 23:30:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183259, encodeId=5d9e218325951, content=偏重的研究方向：肿瘤 经验分享：请问一下这个期刊可以投稿综述吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bef79115167, createdName=ms5000001363351337, createdTime=Mon Jan 22 19:39:14 CST 2024, time=2024-01-22, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2153588, encodeId=9d152153588ef, content=大家几天才变成with editor呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df182456760, createdName=1240adaem89暂无昵称, createdTime=Sat Aug 19 13:53:23 CST 2023, time=2023-08-19, status=1, ipAttribution=四川省)]

2020-01-07 146715bem82(暂无昵称)

我想问一下，送审的话，状态还是under review吗？还是说会改变？asp 2019-02-21 18:52:00 发表:
投了一篇，大修后接受，编辑审稿人效率高。

asp 2019-02-21 18:52:00 发表: 投了一篇，大修后接受，编辑审稿人效率高。

184 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2221084, encodeId=a57722210849a, content=投过3篇GC第一次让大修，各位大佬GC给机会修稿中的概率怎么样。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231102/0c9e5413f4ba4bbdb156bc2a2418ce2e/0236291df9e84588a5c221c5f3033605.jpeg, createdBy=079f1702729, createdName=记录投稿经历, createdTime=Sun Aug 18 13:44:28 CST 2024, time=2024-08-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2124654, encodeId=c2562124654db, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：分子;肿瘤;基础 经验分享：一审一个多月，两个审稿人很专业，给了两个月时间 major revision。二审十天，minor revision 当天修回后三天accept。 编辑的效率非常高，submit后第二天就with editor，隔天就under review。非常不错的杂志，影响因子和声誉都在稳步上升。 目前发文量减少，还是以临床文章为主，缺乏优质的基础研究，希望越办越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=241, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5015158554, createdName=146afc57m84暂无昵称, createdTime=Sun Apr 09 22:11:45 CST 2023, time=2023-04-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=582852, encodeId=6ac958285252, content=我想问一下，送审的话，状态还是under review吗？还是说会改变？asp 2019-02-21 18:52:00 发表: 投了一篇，大修后接受，编辑审稿人效率高。, beContent=asp 2019-02-21 18:52:00 发表: 投了一篇，大修后接受，编辑审稿人效率高。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6715139146, createdName=146715bem82(暂无昵称), createdTime=Tue Jan 07 00:00:00 CST 2020, time=2020-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583965, encodeId=9b6758396532, content=老师，您好，请问这个杂志的版面费贵么nelsontsai 2018-04-27 00:00:00 发表: 投了两篇.一篇审稿约1月拒稿.另一篇一审20天.大修.一个月厚修回.两周接收.编辑和审稿人都很nice.很快., beContent=nelsontsai 2018-04-27 00:00:00 发表: 投了两篇.一篇审稿约1月拒稿.另一篇一审20天.大修.一个月厚修回.两周接收.编辑和审稿人都很nice.很快., objectType=tool_impact_factor, channel=null, level=null, likeNumber=234, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0c002335043, createdName=1227ad64m36暂无昵称, createdTime=Wed Jan 29 00:00:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201934, encodeId=6fb1220193441, content=二审有under review吗？with editor多久能under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6fe5386329, createdName=Jojo, createdTime=Mon May 06 08:53:30 CST 2024, time=2024-05-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=849606, encodeId=99ad84960665, content=审稿速度较快，但是对临床的部分要求严格。给了大修意见，二审四天接收。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=236, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e0b5414039, createdName=ms9688259418763462, createdTime=Sun Feb 03 07:34:23 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567070, encodeId=640556e07089, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：投了一篇，大修后接受，编辑审稿人效率高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=248, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJMC3tF03dm1t2TEOSN9Hiba2iagxaIW7O4RMcQJEESwLxBY5sgv2v1eyXOZd0e7xng6eLxqp7PoSAw/132, createdBy=c2d31631094, createdName=asp, createdTime=Thu Feb 21 18:52:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570704, encodeId=7c095e07046f, content=它收纳肝癌相关的文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/22/0ddfb5f93bf4092dfab0f122ddd93d58.jpg, createdBy=e5902208056, createdName=120cc505m10(暂无昵称), createdTime=Thu May 09 23:30:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183259, encodeId=5d9e218325951, content=偏重的研究方向：肿瘤 经验分享：请问一下这个期刊可以投稿综述吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bef79115167, createdName=ms5000001363351337, createdTime=Mon Jan 22 19:39:14 CST 2024, time=2024-01-22, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2153588, encodeId=9d152153588ef, content=大家几天才变成with editor呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df182456760, createdName=1240adaem89暂无昵称, createdTime=Sat Aug 19 13:53:23 CST 2023, time=2023-08-19, status=1, ipAttribution=四川省)]

2020-01-29 1227ad64m36暂无昵称

老师，您好，请问这个杂志的版面费贵么nelsontsai 2018-04-27 00:00:00 发表:
投了两篇.一篇审稿约1月拒稿.另一篇一审20天.大修.一个月厚修回.两周接收.编辑和审稿人都很nice.很快.

nelsontsai 2018-04-27 00:00:00 发表: 投了两篇.一篇审稿约1月拒稿.另一篇一审20天.大修.一个月厚修回.两周接收.编辑和审稿人都很nice.很快.

234 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2221084, encodeId=a57722210849a, content=投过3篇GC第一次让大修，各位大佬GC给机会修稿中的概率怎么样。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231102/0c9e5413f4ba4bbdb156bc2a2418ce2e/0236291df9e84588a5c221c5f3033605.jpeg, createdBy=079f1702729, createdName=记录投稿经历, createdTime=Sun Aug 18 13:44:28 CST 2024, time=2024-08-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2124654, encodeId=c2562124654db, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：分子;肿瘤;基础 经验分享：一审一个多月，两个审稿人很专业，给了两个月时间 major revision。二审十天，minor revision 当天修回后三天accept。 编辑的效率非常高，submit后第二天就with editor，隔天就under review。非常不错的杂志，影响因子和声誉都在稳步上升。 目前发文量减少，还是以临床文章为主，缺乏优质的基础研究，希望越办越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=241, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5015158554, createdName=146afc57m84暂无昵称, createdTime=Sun Apr 09 22:11:45 CST 2023, time=2023-04-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=582852, encodeId=6ac958285252, content=我想问一下，送审的话，状态还是under review吗？还是说会改变？asp 2019-02-21 18:52:00 发表: 投了一篇，大修后接受，编辑审稿人效率高。, beContent=asp 2019-02-21 18:52:00 发表: 投了一篇，大修后接受，编辑审稿人效率高。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6715139146, createdName=146715bem82(暂无昵称), createdTime=Tue Jan 07 00:00:00 CST 2020, time=2020-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583965, encodeId=9b6758396532, content=老师，您好，请问这个杂志的版面费贵么nelsontsai 2018-04-27 00:00:00 发表: 投了两篇.一篇审稿约1月拒稿.另一篇一审20天.大修.一个月厚修回.两周接收.编辑和审稿人都很nice.很快., beContent=nelsontsai 2018-04-27 00:00:00 发表: 投了两篇.一篇审稿约1月拒稿.另一篇一审20天.大修.一个月厚修回.两周接收.编辑和审稿人都很nice.很快., objectType=tool_impact_factor, channel=null, level=null, likeNumber=234, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0c002335043, createdName=1227ad64m36暂无昵称, createdTime=Wed Jan 29 00:00:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201934, encodeId=6fb1220193441, content=二审有under review吗？with editor多久能under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6fe5386329, createdName=Jojo, createdTime=Mon May 06 08:53:30 CST 2024, time=2024-05-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=849606, encodeId=99ad84960665, content=审稿速度较快，但是对临床的部分要求严格。给了大修意见，二审四天接收。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=236, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e0b5414039, createdName=ms9688259418763462, createdTime=Sun Feb 03 07:34:23 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567070, encodeId=640556e07089, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：投了一篇，大修后接受，编辑审稿人效率高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=248, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJMC3tF03dm1t2TEOSN9Hiba2iagxaIW7O4RMcQJEESwLxBY5sgv2v1eyXOZd0e7xng6eLxqp7PoSAw/132, createdBy=c2d31631094, createdName=asp, createdTime=Thu Feb 21 18:52:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570704, encodeId=7c095e07046f, content=它收纳肝癌相关的文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/22/0ddfb5f93bf4092dfab0f122ddd93d58.jpg, createdBy=e5902208056, createdName=120cc505m10(暂无昵称), createdTime=Thu May 09 23:30:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183259, encodeId=5d9e218325951, content=偏重的研究方向：肿瘤 经验分享：请问一下这个期刊可以投稿综述吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bef79115167, createdName=ms5000001363351337, createdTime=Mon Jan 22 19:39:14 CST 2024, time=2024-01-22, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2153588, encodeId=9d152153588ef, content=大家几天才变成with editor呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df182456760, createdName=1240adaem89暂无昵称, createdTime=Sat Aug 19 13:53:23 CST 2023, time=2023-08-19, status=1, ipAttribution=四川省)]

2024-05-06 Jojo 来自北京

二审有under review吗？with editor多久能under review？

91 0

[GetPortalCommentsPageByObjectIdResponse(id=2221084, encodeId=a57722210849a, content=投过3篇GC第一次让大修，各位大佬GC给机会修稿中的概率怎么样。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231102/0c9e5413f4ba4bbdb156bc2a2418ce2e/0236291df9e84588a5c221c5f3033605.jpeg, createdBy=079f1702729, createdName=记录投稿经历, createdTime=Sun Aug 18 13:44:28 CST 2024, time=2024-08-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2124654, encodeId=c2562124654db, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：分子;肿瘤;基础 经验分享：一审一个多月，两个审稿人很专业，给了两个月时间 major revision。二审十天，minor revision 当天修回后三天accept。 编辑的效率非常高，submit后第二天就with editor，隔天就under review。非常不错的杂志，影响因子和声誉都在稳步上升。 目前发文量减少，还是以临床文章为主，缺乏优质的基础研究，希望越办越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=241, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5015158554, createdName=146afc57m84暂无昵称, createdTime=Sun Apr 09 22:11:45 CST 2023, time=2023-04-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=582852, encodeId=6ac958285252, content=我想问一下，送审的话，状态还是under review吗？还是说会改变？asp 2019-02-21 18:52:00 发表: 投了一篇，大修后接受，编辑审稿人效率高。, beContent=asp 2019-02-21 18:52:00 发表: 投了一篇，大修后接受，编辑审稿人效率高。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6715139146, createdName=146715bem82(暂无昵称), createdTime=Tue Jan 07 00:00:00 CST 2020, time=2020-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583965, encodeId=9b6758396532, content=老师，您好，请问这个杂志的版面费贵么nelsontsai 2018-04-27 00:00:00 发表: 投了两篇.一篇审稿约1月拒稿.另一篇一审20天.大修.一个月厚修回.两周接收.编辑和审稿人都很nice.很快., beContent=nelsontsai 2018-04-27 00:00:00 发表: 投了两篇.一篇审稿约1月拒稿.另一篇一审20天.大修.一个月厚修回.两周接收.编辑和审稿人都很nice.很快., objectType=tool_impact_factor, channel=null, level=null, likeNumber=234, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0c002335043, createdName=1227ad64m36暂无昵称, createdTime=Wed Jan 29 00:00:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201934, encodeId=6fb1220193441, content=二审有under review吗？with editor多久能under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6fe5386329, createdName=Jojo, createdTime=Mon May 06 08:53:30 CST 2024, time=2024-05-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=849606, encodeId=99ad84960665, content=审稿速度较快，但是对临床的部分要求严格。给了大修意见，二审四天接收。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=236, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e0b5414039, createdName=ms9688259418763462, createdTime=Sun Feb 03 07:34:23 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567070, encodeId=640556e07089, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：投了一篇，大修后接受，编辑审稿人效率高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=248, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJMC3tF03dm1t2TEOSN9Hiba2iagxaIW7O4RMcQJEESwLxBY5sgv2v1eyXOZd0e7xng6eLxqp7PoSAw/132, createdBy=c2d31631094, createdName=asp, createdTime=Thu Feb 21 18:52:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570704, encodeId=7c095e07046f, content=它收纳肝癌相关的文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/22/0ddfb5f93bf4092dfab0f122ddd93d58.jpg, createdBy=e5902208056, createdName=120cc505m10(暂无昵称), createdTime=Thu May 09 23:30:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183259, encodeId=5d9e218325951, content=偏重的研究方向：肿瘤 经验分享：请问一下这个期刊可以投稿综述吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bef79115167, createdName=ms5000001363351337, createdTime=Mon Jan 22 19:39:14 CST 2024, time=2024-01-22, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2153588, encodeId=9d152153588ef, content=大家几天才变成with editor呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df182456760, createdName=1240adaem89暂无昵称, createdTime=Sat Aug 19 13:53:23 CST 2023, time=2023-08-19, status=1, ipAttribution=四川省)]

2019-02-03 ms9688259418763462

审稿速度较快，但是对临床的部分要求严格。给了大修意见，二审四天接收。

236 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2221084, encodeId=a57722210849a, content=投过3篇GC第一次让大修，各位大佬GC给机会修稿中的概率怎么样。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231102/0c9e5413f4ba4bbdb156bc2a2418ce2e/0236291df9e84588a5c221c5f3033605.jpeg, createdBy=079f1702729, createdName=记录投稿经历, createdTime=Sun Aug 18 13:44:28 CST 2024, time=2024-08-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2124654, encodeId=c2562124654db, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：分子;肿瘤;基础 经验分享：一审一个多月，两个审稿人很专业，给了两个月时间 major revision。二审十天，minor revision 当天修回后三天accept。 编辑的效率非常高，submit后第二天就with editor，隔天就under review。非常不错的杂志，影响因子和声誉都在稳步上升。 目前发文量减少，还是以临床文章为主，缺乏优质的基础研究，希望越办越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=241, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5015158554, createdName=146afc57m84暂无昵称, createdTime=Sun Apr 09 22:11:45 CST 2023, time=2023-04-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=582852, encodeId=6ac958285252, content=我想问一下，送审的话，状态还是under review吗？还是说会改变？asp 2019-02-21 18:52:00 发表: 投了一篇，大修后接受，编辑审稿人效率高。, beContent=asp 2019-02-21 18:52:00 发表: 投了一篇，大修后接受，编辑审稿人效率高。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6715139146, createdName=146715bem82(暂无昵称), createdTime=Tue Jan 07 00:00:00 CST 2020, time=2020-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583965, encodeId=9b6758396532, content=老师，您好，请问这个杂志的版面费贵么nelsontsai 2018-04-27 00:00:00 发表: 投了两篇.一篇审稿约1月拒稿.另一篇一审20天.大修.一个月厚修回.两周接收.编辑和审稿人都很nice.很快., beContent=nelsontsai 2018-04-27 00:00:00 发表: 投了两篇.一篇审稿约1月拒稿.另一篇一审20天.大修.一个月厚修回.两周接收.编辑和审稿人都很nice.很快., objectType=tool_impact_factor, channel=null, level=null, likeNumber=234, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0c002335043, createdName=1227ad64m36暂无昵称, createdTime=Wed Jan 29 00:00:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201934, encodeId=6fb1220193441, content=二审有under review吗？with editor多久能under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6fe5386329, createdName=Jojo, createdTime=Mon May 06 08:53:30 CST 2024, time=2024-05-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=849606, encodeId=99ad84960665, content=审稿速度较快，但是对临床的部分要求严格。给了大修意见，二审四天接收。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=236, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e0b5414039, createdName=ms9688259418763462, createdTime=Sun Feb 03 07:34:23 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567070, encodeId=640556e07089, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：投了一篇，大修后接受，编辑审稿人效率高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=248, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJMC3tF03dm1t2TEOSN9Hiba2iagxaIW7O4RMcQJEESwLxBY5sgv2v1eyXOZd0e7xng6eLxqp7PoSAw/132, createdBy=c2d31631094, createdName=asp, createdTime=Thu Feb 21 18:52:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570704, encodeId=7c095e07046f, content=它收纳肝癌相关的文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/22/0ddfb5f93bf4092dfab0f122ddd93d58.jpg, createdBy=e5902208056, createdName=120cc505m10(暂无昵称), createdTime=Thu May 09 23:30:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183259, encodeId=5d9e218325951, content=偏重的研究方向：肿瘤 经验分享：请问一下这个期刊可以投稿综述吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bef79115167, createdName=ms5000001363351337, createdTime=Mon Jan 22 19:39:14 CST 2024, time=2024-01-22, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2153588, encodeId=9d152153588ef, content=大家几天才变成with editor呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df182456760, createdName=1240adaem89暂无昵称, createdTime=Sat Aug 19 13:53:23 CST 2023, time=2023-08-19, status=1, ipAttribution=四川省)]

2019-02-21 asp

审稿速度:1.0 | 投稿命中率:50.0
经验分享：投了一篇，大修后接受，编辑审稿人效率高。

248 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2221084, encodeId=a57722210849a, content=投过3篇GC第一次让大修，各位大佬GC给机会修稿中的概率怎么样。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231102/0c9e5413f4ba4bbdb156bc2a2418ce2e/0236291df9e84588a5c221c5f3033605.jpeg, createdBy=079f1702729, createdName=记录投稿经历, createdTime=Sun Aug 18 13:44:28 CST 2024, time=2024-08-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2124654, encodeId=c2562124654db, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：分子;肿瘤;基础 经验分享：一审一个多月，两个审稿人很专业，给了两个月时间 major revision。二审十天，minor revision 当天修回后三天accept。 编辑的效率非常高，submit后第二天就with editor，隔天就under review。非常不错的杂志，影响因子和声誉都在稳步上升。 目前发文量减少，还是以临床文章为主，缺乏优质的基础研究，希望越办越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=241, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5015158554, createdName=146afc57m84暂无昵称, createdTime=Sun Apr 09 22:11:45 CST 2023, time=2023-04-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=582852, encodeId=6ac958285252, content=我想问一下，送审的话，状态还是under review吗？还是说会改变？asp 2019-02-21 18:52:00 发表: 投了一篇，大修后接受，编辑审稿人效率高。, beContent=asp 2019-02-21 18:52:00 发表: 投了一篇，大修后接受，编辑审稿人效率高。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6715139146, createdName=146715bem82(暂无昵称), createdTime=Tue Jan 07 00:00:00 CST 2020, time=2020-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583965, encodeId=9b6758396532, content=老师，您好，请问这个杂志的版面费贵么nelsontsai 2018-04-27 00:00:00 发表: 投了两篇.一篇审稿约1月拒稿.另一篇一审20天.大修.一个月厚修回.两周接收.编辑和审稿人都很nice.很快., beContent=nelsontsai 2018-04-27 00:00:00 发表: 投了两篇.一篇审稿约1月拒稿.另一篇一审20天.大修.一个月厚修回.两周接收.编辑和审稿人都很nice.很快., objectType=tool_impact_factor, channel=null, level=null, likeNumber=234, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0c002335043, createdName=1227ad64m36暂无昵称, createdTime=Wed Jan 29 00:00:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201934, encodeId=6fb1220193441, content=二审有under review吗？with editor多久能under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6fe5386329, createdName=Jojo, createdTime=Mon May 06 08:53:30 CST 2024, time=2024-05-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=849606, encodeId=99ad84960665, content=审稿速度较快，但是对临床的部分要求严格。给了大修意见，二审四天接收。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=236, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e0b5414039, createdName=ms9688259418763462, createdTime=Sun Feb 03 07:34:23 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567070, encodeId=640556e07089, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：投了一篇，大修后接受，编辑审稿人效率高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=248, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJMC3tF03dm1t2TEOSN9Hiba2iagxaIW7O4RMcQJEESwLxBY5sgv2v1eyXOZd0e7xng6eLxqp7PoSAw/132, createdBy=c2d31631094, createdName=asp, createdTime=Thu Feb 21 18:52:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570704, encodeId=7c095e07046f, content=它收纳肝癌相关的文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/22/0ddfb5f93bf4092dfab0f122ddd93d58.jpg, createdBy=e5902208056, createdName=120cc505m10(暂无昵称), createdTime=Thu May 09 23:30:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183259, encodeId=5d9e218325951, content=偏重的研究方向：肿瘤 经验分享：请问一下这个期刊可以投稿综述吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bef79115167, createdName=ms5000001363351337, createdTime=Mon Jan 22 19:39:14 CST 2024, time=2024-01-22, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2153588, encodeId=9d152153588ef, content=大家几天才变成with editor呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df182456760, createdName=1240adaem89暂无昵称, createdTime=Sat Aug 19 13:53:23 CST 2023, time=2023-08-19, status=1, ipAttribution=四川省)]

2019-05-09 120cc505m10(暂无昵称)

它收纳肝癌相关的文章吗？

231 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2221084, encodeId=a57722210849a, content=投过3篇GC第一次让大修，各位大佬GC给机会修稿中的概率怎么样。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231102/0c9e5413f4ba4bbdb156bc2a2418ce2e/0236291df9e84588a5c221c5f3033605.jpeg, createdBy=079f1702729, createdName=记录投稿经历, createdTime=Sun Aug 18 13:44:28 CST 2024, time=2024-08-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2124654, encodeId=c2562124654db, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：分子;肿瘤;基础 经验分享：一审一个多月，两个审稿人很专业，给了两个月时间 major revision。二审十天，minor revision 当天修回后三天accept。 编辑的效率非常高，submit后第二天就with editor，隔天就under review。非常不错的杂志，影响因子和声誉都在稳步上升。 目前发文量减少，还是以临床文章为主，缺乏优质的基础研究，希望越办越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=241, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5015158554, createdName=146afc57m84暂无昵称, createdTime=Sun Apr 09 22:11:45 CST 2023, time=2023-04-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=582852, encodeId=6ac958285252, content=我想问一下，送审的话，状态还是under review吗？还是说会改变？asp 2019-02-21 18:52:00 发表: 投了一篇，大修后接受，编辑审稿人效率高。, beContent=asp 2019-02-21 18:52:00 发表: 投了一篇，大修后接受，编辑审稿人效率高。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6715139146, createdName=146715bem82(暂无昵称), createdTime=Tue Jan 07 00:00:00 CST 2020, time=2020-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583965, encodeId=9b6758396532, content=老师，您好，请问这个杂志的版面费贵么nelsontsai 2018-04-27 00:00:00 发表: 投了两篇.一篇审稿约1月拒稿.另一篇一审20天.大修.一个月厚修回.两周接收.编辑和审稿人都很nice.很快., beContent=nelsontsai 2018-04-27 00:00:00 发表: 投了两篇.一篇审稿约1月拒稿.另一篇一审20天.大修.一个月厚修回.两周接收.编辑和审稿人都很nice.很快., objectType=tool_impact_factor, channel=null, level=null, likeNumber=234, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0c002335043, createdName=1227ad64m36暂无昵称, createdTime=Wed Jan 29 00:00:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201934, encodeId=6fb1220193441, content=二审有under review吗？with editor多久能under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6fe5386329, createdName=Jojo, createdTime=Mon May 06 08:53:30 CST 2024, time=2024-05-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=849606, encodeId=99ad84960665, content=审稿速度较快，但是对临床的部分要求严格。给了大修意见，二审四天接收。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=236, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e0b5414039, createdName=ms9688259418763462, createdTime=Sun Feb 03 07:34:23 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567070, encodeId=640556e07089, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：投了一篇，大修后接受，编辑审稿人效率高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=248, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJMC3tF03dm1t2TEOSN9Hiba2iagxaIW7O4RMcQJEESwLxBY5sgv2v1eyXOZd0e7xng6eLxqp7PoSAw/132, createdBy=c2d31631094, createdName=asp, createdTime=Thu Feb 21 18:52:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570704, encodeId=7c095e07046f, content=它收纳肝癌相关的文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/22/0ddfb5f93bf4092dfab0f122ddd93d58.jpg, createdBy=e5902208056, createdName=120cc505m10(暂无昵称), createdTime=Thu May 09 23:30:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183259, encodeId=5d9e218325951, content=偏重的研究方向：肿瘤 经验分享：请问一下这个期刊可以投稿综述吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bef79115167, createdName=ms5000001363351337, createdTime=Mon Jan 22 19:39:14 CST 2024, time=2024-01-22, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2153588, encodeId=9d152153588ef, content=大家几天才变成with editor呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df182456760, createdName=1240adaem89暂无昵称, createdTime=Sat Aug 19 13:53:23 CST 2023, time=2023-08-19, status=1, ipAttribution=四川省)]

2024-01-22 ms5000001363351337 来自湖北省

偏重的研究方向：肿瘤
经验分享：请问一下这个期刊可以投稿综述吗

113 0

[GetPortalCommentsPageByObjectIdResponse(id=2221084, encodeId=a57722210849a, content=投过3篇GC第一次让大修，各位大佬GC给机会修稿中的概率怎么样。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231102/0c9e5413f4ba4bbdb156bc2a2418ce2e/0236291df9e84588a5c221c5f3033605.jpeg, createdBy=079f1702729, createdName=记录投稿经历, createdTime=Sun Aug 18 13:44:28 CST 2024, time=2024-08-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2124654, encodeId=c2562124654db, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：分子;肿瘤;基础 经验分享：一审一个多月，两个审稿人很专业，给了两个月时间 major revision。二审十天，minor revision 当天修回后三天accept。 编辑的效率非常高，submit后第二天就with editor，隔天就under review。非常不错的杂志，影响因子和声誉都在稳步上升。 目前发文量减少，还是以临床文章为主，缺乏优质的基础研究，希望越办越好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=241, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5015158554, createdName=146afc57m84暂无昵称, createdTime=Sun Apr 09 22:11:45 CST 2023, time=2023-04-09, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=582852, encodeId=6ac958285252, content=我想问一下，送审的话，状态还是under review吗？还是说会改变？asp 2019-02-21 18:52:00 发表: 投了一篇，大修后接受，编辑审稿人效率高。, beContent=asp 2019-02-21 18:52:00 发表: 投了一篇，大修后接受，编辑审稿人效率高。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6715139146, createdName=146715bem82(暂无昵称), createdTime=Tue Jan 07 00:00:00 CST 2020, time=2020-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583965, encodeId=9b6758396532, content=老师，您好，请问这个杂志的版面费贵么nelsontsai 2018-04-27 00:00:00 发表: 投了两篇.一篇审稿约1月拒稿.另一篇一审20天.大修.一个月厚修回.两周接收.编辑和审稿人都很nice.很快., beContent=nelsontsai 2018-04-27 00:00:00 发表: 投了两篇.一篇审稿约1月拒稿.另一篇一审20天.大修.一个月厚修回.两周接收.编辑和审稿人都很nice.很快., objectType=tool_impact_factor, channel=null, level=null, likeNumber=234, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0c002335043, createdName=1227ad64m36暂无昵称, createdTime=Wed Jan 29 00:00:00 CST 2020, time=2020-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201934, encodeId=6fb1220193441, content=二审有under review吗？with editor多久能under review？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d6fe5386329, createdName=Jojo, createdTime=Mon May 06 08:53:30 CST 2024, time=2024-05-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=849606, encodeId=99ad84960665, content=审稿速度较快，但是对临床的部分要求严格。给了大修意见，二审四天接收。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=236, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e0b5414039, createdName=ms9688259418763462, createdTime=Sun Feb 03 07:34:23 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567070, encodeId=640556e07089, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：投了一篇，大修后接受，编辑审稿人效率高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=248, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJMC3tF03dm1t2TEOSN9Hiba2iagxaIW7O4RMcQJEESwLxBY5sgv2v1eyXOZd0e7xng6eLxqp7PoSAw/132, createdBy=c2d31631094, createdName=asp, createdTime=Thu Feb 21 18:52:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=570704, encodeId=7c095e07046f, content=它收纳肝癌相关的文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=231, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/22/0ddfb5f93bf4092dfab0f122ddd93d58.jpg, createdBy=e5902208056, createdName=120cc505m10(暂无昵称), createdTime=Thu May 09 23:30:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2183259, encodeId=5d9e218325951, content=偏重的研究方向：肿瘤 经验分享：请问一下这个期刊可以投稿综述吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bef79115167, createdName=ms5000001363351337, createdTime=Mon Jan 22 19:39:14 CST 2024, time=2024-01-22, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2153588, encodeId=9d152153588ef, content=大家几天才变成with editor呀？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df182456760, createdName=1240adaem89暂无昵称, createdTime=Sat Aug 19 13:53:23 CST 2023, time=2023-08-19, status=1, ipAttribution=四川省)]

2023-08-19 1240adaem89暂无昵称来自四川省

大家几天才变成with editor呀？

128 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务